Tag: GlobeNewswire

LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.

A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com 

Company Contact
irteam@immixbio.com 

Companies to Meet Formally with FDA’s Center for Veterinary Medicine on November 19th for Pre-Submission Conference; U.S. Manufacturing Strategy Underway to Support Potential 2027 Veterinary Product Launch

FORT LAUDERDALE, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) — Endovia Health Sciences, Inc. (“Endovia” or the “Company”) (NYSE American: EDVA), in association with Lupvindol BioSciences (“Lupvindol”), today announced that the U.S. Food and Drug Administration’s (“FDA”) Center for Veterinary Medicine has determined that the proposed use of CannEpil^®, an investigational cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) oral solution, for the control of pain associated with bone cancer in dogs qualifies as a “minor use” under the Minor Use and Minor Species (“MUMS”) program.

The FDA determination establishes CannEpil’s eligibility to pursue the conditional approval pathway for this proposed indication. The FDA further determined that the minor-use status will be maintained through approval of the applicable New Animal Drug Application (“NADA”).

Under the MUMS framework, qualifying new animal drugs may be eligible for conditional approval which is a regulatory pathway designed to facilitate earlier availability of therapies for uncommon diseases and conditions in animals. Conditional approval requires satisfaction of applicable FDA requirements, including safety and manufacturing standards and a reasonable expectation of effectiveness, while allowing additional effectiveness data required for full approval to be collected following conditional approval.

Endovia and Lupvindol are scheduled to meet formally with the FDA on November 19, 2026, for a Pre-Submission Conference to discuss and align with the FDA on the proposed CannEpil^® development program, including the studies, manufacturing requirements and regulatory submissions necessary to pursue conditional approval.

In parallel with the regulatory program, Endovia and Lupvindol are actively sourcing and finalizing U.S.-based manufacturing capabilities for CannEpil^®. This work is intended to establish a scalable, FDA-compliant domestic supply chain capable of supporting the clinical and regulatory program and, subject to receipt of the necessary regulatory approvals, a potential commercial launch for veterinary use in 2027.

“This determination represents an important regulatory milestone for CannEpil^® and provides greater clarity around the pathway we are pursuing with the FDA,” said Brady Cobb, Interim Chief Executive Officer of Endovia Health Sciences. “Importantly, we are not waiting to begin preparing for commercialization. Alongside Lupvindol, we are advancing our FDA development program while simultaneously working to establish U.S. manufacturing and supply capabilities that can support a potential veterinary launch in 2027, subject to regulatory approval.”

Cobb continued, “We believe CannEpil has the potential to demonstrate what a science-driven, federally regulated cannabinoid medicine can look like in the United States. Our veterinary program gives us an opportunity to address a serious unmet need for dogs suffering from cancer-related pain while building the regulatory, manufacturing and scientific infrastructure that we believe can support the broader development of CannEpil.”

The MUMS conditional approval pathway was established to encourage development of new animal drugs for uncommon conditions affecting relatively small populations. Following conditional approval, a sponsor may legally market a qualifying animal drug while continuing to collect the additional effectiveness data necessary to support full FDA approval, subject to applicable statutory and regulatory requirements and annual FDA renewal.

CannEpil^® remains an investigational new animal drug and has not been approved or conditionally approved by the FDA. The Company’s anticipated development timelines, including a potential 2027 commercial launch, remain subject to FDA review, successful completion of applicable regulatory requirements, manufacturing readiness and other factors.

About CannEpil^®

CannEpil^® is a proprietary cannabinoid-based oral formulation containing cannabidiol (CBD) and tetrahydrocannabinol (THC). Endovia and Lupvindol BioSciences are advancing CannEpil through the FDA’s Center for Veterinary Medicine for the proposed control of pain associated with bone cancer in dogs.

The veterinary development program is part of Endovia’s broader strategy to develop cannabinoid-based therapeutics through established federal regulatory pathways and to build a platform capable of supporting additional veterinary and human therapeutic applications, subject to applicable statutory and regulatory requirements.

About Endovia Health Sciences

Endovia Health Sciences, Inc. (NYSE American: EDVA) is a cannabinoid health sciences company focused on building a diversified platform across pharmaceutical development, FDA-regulated human and veterinary therapeutics, international pharmaceutical commercialization and cannabinoid-based wellness products.

About Lupvindol Biosciences Ltd.

Lupvindol Biosciences Ltd. is a pharmaceutical and bioscience development company with expertise in cannabinoid-based therapeutics and U.S. FDA regulatory pathways. The company is led by Hunter Land, Ph.D., whose experience includes participation in the development of Epidiolex^® and Sativex^® at GW Pharmaceuticals.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform act of 1995 including statements regarding the development and commercialization of CannEpil^®; obtaining a manufacturing source, and a potential commercial veterinary launch in 2027.

Forward-looking statements are based on current expectations, estimates, projections and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Some or all of these risks may not occur. These risks include the Company’s ability to obtain additional financing; the development of and obtaining regulatory authorization for and commercialize CannEpil^® for veterinary use, the results of any clinical trials, the availability of raw materials, the ability to obtain a manufacturer to meet our needs on a financially viable basis, ; maintaining its rights under applicable license agreements; the enactment, implementation or impact of proposed legislation or regulatory initiatives; ability to meet competition from both CBD and conventional pharmaceuticals products ,our ability to successfully execute commercialization or strategic-partnering arrangements, and the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected.

Additional risks are described in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the final prospectus filed pursuant to Rule 424(b)(3) on August 28, 2026.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any such statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Contact
Endovia Health Sciences
investors@endoviasciences.com

Media Contact
Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083

Second tranche completes the strategic relationship announced on June 16, 2026, adding exposure to anorthosite — an aluminum-rich rock characteristic of the lunar highlands — for sustainable alumina, refractory systems, lunar regolith simulants and research into 3D-printed lunar construction materials

CHARLOTTE, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) — via IBN — Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML; FSE: HK6), a Greenland-focused critical-minerals development company, today announced that it has exercised in full its option to acquire an additional 9.9% of Anortech.

When Greenland Mines made its initial investment in June, the Company described AnorTech as a differentiated critical-materials and processing platform: sustainable smelter-grade alumina, high-purity alumina, CO2-free cement, and related industrial materials from AnorTech’s 100%-owned Gronne Bjerg anorthosite project, approximately 80 kilometers from the capital of Nuuk on open tidewater. Greenland Mines sees Gronne Bjerg as a potential source of feedstock for U.S. smelter-grade and high-purity alumina production in a market where net imports met an estimated 71% of U.S. alumina consumption in 2025, according to the U.S. Geological Survey. Today’s exercise reflects a second, and increasingly important, dimension of that platform — anorthosite’s potential role in lunar construction research.

Anorthosite — a rock composed predominantly of plagioclase feldspar — is a major component of the lunar highlands. Terrestrial anorthosite can serve as an analogue for aspects of lunar highlands geology and as a component of lunar regolith simulants. AnorTech reports that it has supplied its anorthosite to space-sector researchers for use as a lunar simulant.

AnorTech reports that its natural anorthosite shares compositional and mineralogical characteristics with lunar highlands materials, supporting the development and testing of technologies on Earth. Over more than a decade, it has advanced anorthosite-based lunar regolith simulants, 3D-printable concrete and construction materials, refractory concretes and cements, and both smelter-grade and high-purity alumina production. Its work includes research into potential lunar construction applications; deployment would require further testing under lunar conditions.

Greenland Mines’ strategy is to build a critical-materials platform spanning advantaged upstream assets in Greenland and U.S. refining and manufacturing opportunities, supported by partnerships in allied jurisdictions — the Company’s North Atlantic Critical Metals Corridor. AnorTech extends that platform in two directions:

Exposure to proprietary, patent-pending processes to produce sustainable smelter-grade and high-purity alumina from anorthosite without bauxite-residue tailings, generating saleable amorphous-silica and calcium silicate by-products, together with CO2-free refractory cement, 3D-printable cement and alumina-based catalysts. AnorTech has shipped 15 tons of Gronne Bjerg anorthosite to Ontario in preparation for pilot-plant testing. AnorTech reports that its alumina flowsheet has been demonstrated at laboratory scale, with a planned pilot program intended to produce smelter-grade and high-purity alumina samples for engineering tests and customer evaluation.

Potential dual-use applications — including simulants, printable construction materials, refractories and resource-processing technologies — relevant to research on using the Moon’s own materials for construction and reducing the amount of material that must be transported from Earth.

The characteristics that make Gronne Bjerg attractive as a terrestrial industrial-minerals project — a massive and homogeneous anorthosite body averaging 32% aluminum oxide, on deep-water tidewater approximately 80 kilometers from Nuuk and its international airport, adjacent to significant hydroelectric potential — could also support the supply of lunar-analogue material for research and testing on Earth. Greenland Mines sees the project’s tidewater location as a potential link between feedstock from a friendly North Atlantic jurisdiction and future U.S. alumina refining, helping bring more processing and manufacturing value into the United States. Greenland Mines believes the combination of AnorTech’s materials science and Greenland’s resource base positions the group to participate in space-materials research, defence, advanced-manufacturing and supply-chain-security themes that are increasingly central to allied industrial policy.

Bo Møller Stensgaard, President of Greenland Mines, commented:

“Rebuilding America’s aluminum and advanced-materials industries requires secure feedstock and more refining capacity on U.S. soil. We see the opportunity to connect Greenland resources with U.S. production of smelter-grade alumina for American aluminum smelters and high-purity alumina for semiconductor and other advanced-materials supply chains. The objective is a supply chain from Greenland to the United States that can operate independently of Chinese refining, with more processing, manufacturing and value creation in America. That is how feedstock from friendly shores could support greater U.S. industrial self-sufficiency.

“Alongside that U.S. industrial opportunity, AnorTech’s simulants and materials development support research on lunar surface infrastructure and the use of local resources for construction. Doubling our position gives Greenland Mines shareholders exposure to this U.S. industrial strategy, alongside longer-term potential in lunar applications.”

Jim Cambon, President of AnorTech, commented:

“Greenland Mines’ decision to exercise its option in full is a strong endorsement of what we are building at AnorTech. Greenland Mines understands the value we are creating from Greenland anorthosite and its exciting future as a key component in the aluminum critical mineral supply chain and as a material for research into future lunar construction. We are moving our smelter grade alumina and high purity alumina technologies towards commercialization while continuing our successful test programs on 3D-printable and refractory cements, which may also inform future lunar construction applications. We are working with a number of groups in the space industry who are using our anorthosite as a lunar simulant and we expect this sector to grow as lunar programs ramp up.  We look forward to maximizing the synergies between our companies and working with Greenland Mines as a strategic shareholder as we advance our lunar materials, smelter grade alumina and high purity alumina programs.”

Transaction Terms

The option to acquire an additional 9.9% of AnorTech was granted under the share exchange agreement between the Company and AnorTech dated June 15, 2026, announced on June 16, 2026, and completed on June 22, 2026, through which Greenland Mines acquired its initial 19,958,503 AnorTech shares. On completion of the exercise, Greenland Mines will hold 45,127,172 AnorTech shares.

Under the option granted to Greenland Mines pursuant to the share exchange agreement dated June 15, 2026 (the “Option”), the Company has exercised the Option in full to acquire 25,168,669 AnorTech common shares (the “Option Shares”) at a deemed price of C$0.30 per Option Share, for aggregate consideration of approximately US$5,298,000 (C$7,550,000). The consideration is satisfied through the issuance by Greenland Mines to AnorTech of common shares of Greenland Mines, with the exact number of shares based on the 10-day volume-weighted average trading price of the Greenland Mines common shares on Nasdaq at the time of closing.

Following the issuance of the Option Shares, Greenland Mines will own 45,127,172 AnorTech common shares, representing 19.9% of AnorTech’s issued and outstanding share capital. The Option Shares are subject to a contractual lock-up of 60 months from issuance, consistent with the initial tranche, in addition to a four-month Canadian statutory hold period. One-half of the Greenland Mines shares issued to AnorTech are subject to a 12-month contractual lock-up and the remaining one-half to a 24-month contractual lock-up. AnorTech currently owns 318,000 shares of Greenland Mines from previous transactions. The Greenland Mines shares will be issued in a private transaction exempt from the registration requirements of the U.S. Securities Act of 1933, as amended. Completion of the exercise is subject to acceptance by the TSX Venture Exchange and customary closing conditions.

About Greenland Mines Ltd

Greenland Mines Ltd is a Nasdaq-listed resource development and mining company focused on the development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and select midstream processing opportunities, while advancing its assets and broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

About AnorTech Inc.

AnorTech (formerly Hudson Resources Inc.) is pioneering the next generation of sustainable materials from anorthosite with over 12 years experience in developing anorthosite products and 25 years experience exploring, building and operating projects in Greenland. The Company owns 100% of the Gronne Bjerg anorthosite project in Greenland — strategically located approximately 80 km from Nuuk, the capital of Greenland, on open tidewater and adjacent to significant hydroelectric potential. AnorTech is advancing multiple product lines towards commercialization, including zero-waste smelter grade alumina (SGA) and high purity alumina (HPA); next generation alumina-based catalysts for CO2 capture; CO2-free refractory cement and advanced 3D-printable cement; and research into lunar construction materials using anorthosite-based concrete. Its high-purity alumina development work could support a domestic U.S. supply of advanced materials, including synthetic sapphire for semiconductor applications, by combining Greenland feedstock with potential U.S. refining and manufacturing. AnorTech filed a U.S. provisional patent in 2025 to protect its proprietary sustainable SGA and HPA process and has shipped 15 tons of Gronne Bjerg anorthosite to Ontario in preparation for pilot plant testing. AnorTech has over C$3 million in working capital.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate,” “objective” and similar expressions. These forward-looking statements include statements regarding the completion of the exercise of the Option and the issuance of the Option Shares and the Greenland Mines shares, the receipt of TSX Venture Exchange acceptance, the strategic benefits of the Company’s investment in AnorTech, AnorTech’s proposed Anorthosite Lunar Materials Innovation Program and any partnership, funding or agreement in respect of it, the suitability of Gronne Bjerg anorthosite as a lunar regolith simulant or as feedstock for lunar construction materials, refractory systems or alumina, the future commercialization of AnorTech’s technologies, future pilot plant activities, future demand from space, defence and advanced-manufacturing markets, the development of a North Atlantic Critical Metals Corridor and the Company’s broader strategy.

These statements are based on current expectations, assumptions and available information and are subject to a range of risks and uncertainties, including regulatory and exchange approvals, technical and commercialization risk, pilot scale-up risk, the risk that no agreement in respect of AnorTech’s proposed lunar materials program is concluded with any space agency or commercial space company, the timing and scope of governmental and commercial lunar programs, market conditions, financing availability, industrial partner engagement, logistics constraints and project execution risk, as well as the exploration, resource-estimation, metallurgical, engineering, environmental, social, permitting, infrastructure, commodity-price, counterparty and other risks described in documents filed or to be filed with the U.S. Securities and Exchange Commission, any of which could cause actual results to differ materially from those expressed or implied. Statements in this press release regarding AnorTech, its technologies, its Gronne Bjerg project and its proposed lunar materials program are based on information provided by or publicly disclosed by AnorTech, which Greenland Mines has not independently verified. Greenland Mines holds a minority interest in, and does not control, AnorTech. No assurance can be given that studies, partnerships, transactions, development decisions or production will occur on the timing contemplated or at all.

Readers should carefully consider these factors and the other risks and uncertainties described in the Company’s SEC filings. All information in this press release is provided as of its date, and the Company undertakes no obligation to update any forward-looking statement except as required by applicable law.

Investor Contact and Corporate Communications:

ir@greenlandmines.com
Website: www.greenlandmines.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Five-year ordering period through September 2031 positions Cyabra to compete to supply AI-powered image and video analysis that uncovers manipulated, synthetic, and inauthentic content

New York, NY, Oct. 05, 2026 (GLOBE NEWSWIRE) —  Cyabra, Inc. (Nasdaq: CYAB) (“Cyabra” or the “Company”), an artificial intelligence (“AI”)-powered narrative intelligence company that helps governments and enterprises detect coordinated manipulation and protect digital trust, today announced that its wholly owned subsidiary, Cyabra Strategy Inc., has been awarded positions under both the Image Information and Video Information categories of the Federal Bureau of Investigation’s (FBI) Specialized Open-Source Intelligence (OSINT) Tools multi-award Indefinite Delivery, Indefinite Quantity (IDIQ) contract.

The five-year ordering period runs through September 2031, during which Cyabra is eligible to compete for task orders from FBI headquarters divisions and field offices across the United States.

As generative AI tools make deepfake videos, altered imagery, and synthetic visual content faster, cheaper, and harder to detect manually, federal law enforcement and intelligence agencies increasingly need scalable, evidence-based analysis. Cyabra’s narrative intelligence platform, delivered as cloud-native SaaS, equips analysts with authenticity scoring and supporting forensic signals for images and video. Capabilities include detection of GAN- and diffusion-generated content, face swaps and splice points, plus C2PA content-provenance checks and account authenticity scoring for context on who is sharing the content.

“When an image or video surfaces in an investigation, the first question is whether it is real, and the next is whether the account sharing it is authentic,” said Dan Brahmy, Co-Founder and CEO of Cyabra. “The FBI’s decision to create dedicated image and video categories signals that investigative demand is moving toward evidence-based answers that hold up under scrutiny. Selection in both positions Cyabra to compete for that demand, and we are committed to building our U.S. public sector business, where we see significant opportunity.”

“Our selection for this FBI contract vehicle reflects the strength of Cyabra’s visual AI analysis capabilities,” said Keith E. Noble, Ph.D., Vice President of U.S. Government Sales at Cyabra. “This IDIQ gives FBI divisions a streamlined way to acquire image and video analysis in support of their investigative missions, and we look forward to competing to provide ours.”

Selection for the FBI’s Specialized OSINT Tools IDIQ vehicle is an important step in Cyabra’s federal expansion strategy. It builds on Cyabra’s existing public-sector contract vehicles and channel partnerships serving U.S. federal, defense, and intelligence agencies. Cyabra believes the award establishes a pathway to recurring federal license revenue and a credible reference point as the Company pursues additional federal opportunities.

About Cyabra

Cyabra is an AI-powered narrative intelligence company that helps national security and defense organizations, government agencies, brands, communications agencies, and global enterprises restore trust and authenticity online by analyzing manipulated content, coordinated behaviors, and inauthentic actors. The platform helps teams understand who is operating, how activity is amplified, and where coordinated activity is shaping perception, translating evidence into clear mitigation steps. By reducing ambiguity and misdirected response, Cyabra enables proportionate, evidence-led action when clarity matters most.
For more information, visit www.cyabra.com.

Contact:

Investors: ir@cyabra.com
Media: pr@cyabra.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding Cyabra’s intent, belief, or expectations, including, but not limited to, statements regarding Cyabra’s future results of operations and financial position, planned products and services, business strategy and plans, market size and growth opportunities, competitive position and market trends. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. For example, the Company is using forward-looking statements in this press release when it discusses the IDIQ contract, the potential issuance of task orders under the contract, the anticipated use of Cyabra’s image and video analysis capabilities by FBI divisions and field offices, anticipated demand for such capabilities, the potential for recurring federal license revenue, and Cyabra’s federal expansion strategy. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, that the IDIQ contract does not guarantee that Cyabra will receive task orders of any material value; Cyabra’s ability to compete successfully for task orders against other awardees; Cyabra’s ability to satisfy government security and personnel requirements before providing access to FBI users; the Government’s right to suspend or remove Cyabra from the contract following security reviews; the availability of government funding and changes in government procurement priorities; and those set forth in Cyabra’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Cyabra undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Expands technology portfolio and addressable market, with $500 million or more in expected annual cost synergies and immediate non-GAAP EPS accretion

IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Skyworks (Nasdaq: SWKS) today announced the successful completion of its combination with Qorvo. The close of the transaction creates a U.S.-based, global leader in high-performance radio frequency (RF), power management, and analog and mixed-signal semiconductor solutions. 

“This combination is about far more than bringing two companies together,” said Phil Brace, chief executive officer and president of Skyworks. “Our customers are tackling increasingly complex challenges and need partners with the capabilities, engineering expertise and scale to help them innovate faster. Together, we are well positioned to deliver more integrated, system-level solutions and accelerate the next generation of connected technologies. Today marks an important milestone—but it is only the beginning. We see an extraordinary opportunity to create long-term value for our customers, shareholders and employees while helping shape the future of our industry.”

The transaction creates a larger, more diversified semiconductor company, combining complementary RF, analog, and power technologies with expanded engineering capabilities — approximately 8,000 engineers and more than 12,000 issued and pending patents. 

In Mobile, the combination broadens its RF front-end portfolio, positioning the company to benefit from rising RF complexity. As 5G-Advanced evolves and the industry moves toward 6G, smartphones are expected to support more frequency bands, new spectrum and AI-driven features, increasing demand for highly integrated RF solutions.

Beyond Mobile, the combination more than doubles Skyworks’ addressable market and establishes a platform spanning physical AI and connected edge, defense and aerospace, data center and networking, and automotive. It also broadens the technology portfolio into RF GaN, low-voltage power, and wired broadband.

Skyworks will benefit from greater end-market breadth, strengthened domestic manufacturing, and annualized cost synergies of $500 million or more, expected to be realized within 24 to 36 months post-close when the companies are fully integrated. 

The transaction is expected to be immediately accretive to non-GAAP EPS while maintaining a favorable capital structure. Skyworks will provide financial guidance on its fiscal fourth-quarter earnings call on Nov. 3. 

Bob Bruggeworth, former chief executive officer and president of Qorvo and a member of the Skyworks Board of Directors, added, “This next chapter begins with an immense amount of pride. I’ve had the opportunity to see firsthand our teams preparing for this moment with tremendous focus and discipline. I have great confidence in the future of the combined company and its ability to deliver on the promise of the combination.”

Under the terms of the merger agreement, Qorvo shareholders are entitled to receive $32.50 in cash and 0.960 of Skyworks’ common share for each share of Qorvo common stock they owned. Legacy Skyworks shareholders own approximately 63% of the combined company and legacy Qorvo shareholders own approximately 37%, on a fully diluted basis. The company will continue to operate as Skyworks and trade under the SWKS ticker symbol on the NASDAQ market.

As previously announced, Phil Brace will continue to serve as chief executive officer and president of Skyworks. Bob Bruggeworth, Richard Clemmer and Chris Koopmans, formerly on the Qorvo board of directors, have each joined the Skyworks Board of Directors. 

Advisors
Qatalyst Partners and Goldman Sachs & Co. LLC acted as financial advisors to Skyworks, with Skadden, Arps, Slate, Meagher & Flom LLP serving as Skyworks’ legal advisor.

Centerview Partners LLC was exclusive financial advisor and Davis Polk & Wardwell LLP acted as legal advisor to Qorvo.

About Skyworks 
Skyworks® is a global leader in high-performance RF, precision timing, power management and mixed-signal solutions that power the intelligent, connected world. Through deep engineering expertise, Skyworks helps customers address rising complexity and deliver seamless connectivity across smartphones, vehicles, networks and critical infrastructure.

From defense and aerospace systems to the connected edge, AI infrastructure and next-generation automotive platforms, Skyworks provides the essential technologies that connect, synchronize and power physical AI, as intelligence moves out of the data center and into the real world. Harnessing decades of technical leadership and trusted partnerships across the technology ecosystem, Skyworks helps the world’s leading innovators bring next-generation products and services to market. 

Skyworks is a member of the S&P 500® market index (Nasdaq: SWKS). For more information, please visit www.skyworksinc.com.

Forward Looking Statements

This press release includes “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include information relating to future events, prospects, expectations and results of Skyworks (e.g., certain projections and business trends, including with respect to future sales and revenue, as well as statements regarding the recently completed combination with Qorvo, Inc. (“Qorvo”)). Forward-looking statements can often be identified by words such as “anticipates,” “estimates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. All such statements are subject to certain risks, uncertainties and other important factors that could cause actual results to differ materially and adversely from those projected and may affect our future operating results, financial position and cash flows.

These risks, uncertainties and other important factors include: the potential impacts on our business, reputation, relationships, results of operations, cash flows and financial condition as a result of the combination with Qorvo, Inc.; the possibility that expected benefits related to such transactions with Qorvo may not materialize as expected; our business experiencing disruptions as a result of the acquisition, including factors making it more difficult to maintain relationships with employees, customers, other business partners or governmental entities; the diversion of management time to integration of the business; our being unable to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all; the costs, fees, expenses and other charges related to the transactions with Qorvo, including with respect to any related litigation; reduced flexibility in operating our business as a result of the substantial amount of additional indebtedness we have incurred and may in the future incur in connection with the Qorvo transactions; unexpected costs, charges and expenses related to the integration of the parties’ businesses; the risks of doing business internationally, including from trade war or trade protection measures (e.g., tariffs, retaliatory tariffs and other countermeasures or taxes), increased import/export restrictions and controls (e.g., our ability to obtain foreign-sourced raw materials, including from Chinese-based sources, as well as our ability to sell products to certain specified foreign entities only pursuant to a limited export license from the U.S. Department of Commerce), the susceptibility of the semiconductor industry and the markets addressed by our, and our customers’, products to economic cycles or changes in economic conditions, including inflation and recession that could result from trade war or trade protection measures; our reliance on a small number of key customers for a large percentage of our sales; decreased gross margins and loss of market share as a result of increased competition; our ability to obtain design wins from customers; our ability to convert design wins into revenue; market acceptance of our products and our customers’ products, including market acceptance of new, emerging technologies such as AI; the mix and volume of phone models sold by our largest customer; delays in the deployment of commercial 5G networks or in consumer adoption of 5G-enabled devices; the volatility of our stock price; changes in laws, regulations and/or policies that could adversely affect our operations and financial results, the economy and our customers’ demand for our products, or the financial markets and our ability to raise capital; fluctuations in our manufacturing yields due to our complex and specialized manufacturing processes; our ability to develop, manufacture and market innovative products, avoid product obsolescence, reduce costs in a timely manner, transition our products to smaller geometry process technologies and achieve higher levels of design integration; the quality of our products and any defect remediation costs; our products’ ability to perform under stringent operating conditions; the availability and pricing of third-party semiconductor foundry, assembly and test capacity, raw materials, including rare earth and similar minerals, supplier components, equipment and shipping and logistics services, including limits on our customers’ ability to obtain such services and materials; risks that we may not be able to optimize our manufacturing footprint and achieve any financial and operational benefits from such efforts, including reducing fixed costs or improving utilization rates, disruptions to our manufacturing processes, including relating to any relocation of our key facilities; our ability to successfully manage our senior management transitions; our ability to retain, recruit and hire key executives or the departure of any such executives, technical personnel and other employees in the positions and numbers, with the experience and capabilities, and at the compensation levels needed to implement our business and product plans; the timing, rescheduling or cancellation of significant customer orders and our ability, as well as the ability of our customers, to manage inventory; other economic, social, military and geopolitical conditions in the countries in which we, our customers or our suppliers operate, including the conflicts in Ukraine, Iran and other regions in the Middle East, possible disruptions in transportation networks, and fluctuations in foreign currency exchange rates; the effects of global health crises on business conditions in our industry, including the risk of significant disruptions to our business operations, as well as negative impacts to our financial condition; our ability to prevent theft of our intellectual property, disclosure of confidential information or breaches of our information technology systems; uncertainties of litigation, including potential disputes over intellectual property infringement and rights, as well as payments related to the licensing and/or sale of such rights; our ability to continue to grow and maintain an intellectual property portfolio and obtain needed licenses from third parties; our ability to make certain investments and acquisitions, integrate Qorvo and other companies we acquire and/or enter into strategic alliances; and other risks and uncertainties, including those detailed from time to time in our filings with the Securities and Exchange Commission.

The forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Note to Editors: Skyworks, Qorvo, the Skyworks symbol, and the Qorvo symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.

Media Relations:         Constance Griffiths (949) 230-4867         Constance.Griffiths@skyworks.com

Investor Relations: Raji Gill (949) 508-0973 Raji.Gill@skyworks.com

Bagsværd, Denmark, 5 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 28 September, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	20,620,000		6,139,842,042
28 September 2026	245,000	253.30	62,059,136
29 September 2026	245,000	252.74	61,921,920
30 September 2026	245,000	250.50	61,372,450
1 October 2026	245,000	249.50	61,126,718
2 October 2026	245,000	248.77	60,948,613
Accumulated under the programme	21,845,000		6,447,270,879

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 50,644,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 2 October 2026, Novo Nordisk has since 4 February 2026 repurchased a total 36,604,179 B shares at an average share price of DKK 279.95 per B share equal to a transaction value of DKK 10,247,270,869.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com	Max Ung +45 3077 6414 mxun@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com	Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com

Company announcement No 60 / 2026

Attachments

• CA261005_Safe Harbour
• CA261005_Safe harbour transaction details

AUSTIN, Texas, Oct. 05, 2026 (GLOBE NEWSWIRE) — Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), a provider of AI-enabled guest intelligence software to operators of hotels, resorts and other large, complex properties, today announced that Phunware’s CEO, Dmitry Kroshka, will host an in-person presentation and one-on-one meetings at the LD Micro 20th Annual Main Event, taking place October 20–21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Mr. Kroshka’s presentation will highlight Phunware 2.0, the Company’s repositioning around the Guest Intelligence Platform, which is sold as a recurring subscription per property and expanded module by module. The platform brings together location, property management and transactional data to help guests discover what a property offers, find their way around it and book dining, spa services and activities, and to give operators a clearer view of what their guests want and ancillary income generated. He will also discuss AI Concierge, which was commercially released in January 2026 and is in production, the Company’s roadmap for the AI Itinerary Builder and the Location-Aware Data Layer, and the planned expansion of the platform beyond hospitality into healthcare campuses and senior living.

LD Micro Main Event XX
Date: October 20–21, 2026
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA
Conference Website: Click here
Format: In-person Presentation and 1×1 meetings
Presentation: Tuesday, October 20, 2026, 10:30 a.m. PT (1:30 p.m. ET), Track 3
Webcast Registration: Click here
Attendees: Chief Executive Officer Dmitry Kroshka

To schedule a one-on-one meeting with Phunware management, please contact your conference representative, email your request to PHUN@mzgroup.us, or call Chris Tyson at (949) 491-8235.

About Phunware

Phunware, Inc. (NASDAQ: PHUN) is an enterprise software company specializing in mobile app solutions for hospitality, healthcare and other large property related customers, with integrated intelligent capabilities. We provide businesses with the tools to create, implement, and manage custom mobile applications, analytics, and location-based services. Phunware is transforming mobile engagement by delivering scalable, personalized, and data-driven mobile app experiences.

Phunware’s mission is to achieve unparalleled connectivity and monetization through the widespread adoption of Phunware mobile technologies, leveraging brands, consumers, partners, and market participants. Phunware is poised to expand its software products and services audience through new generative AI products and product enhancements which are in development, utilize and monetize its patents and other intellectual property, and focus on serving its enterprise customers and partners.

For more information on Phunware, please visit www.phunware.com.

Safe Harbor / Forward-Looking Statements

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy and plans, our objectives for future operations, the development and commercial rollout of our Product 2.0 strategy and Guest Intelligence Platform, the performance and adoption of our AI Concierge, AI Itinerary Builder, and Location-Aware Data Layer capabilities, the expansion of our product offering into adjacent end markets, and the timing of upcoming investor and industry events, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” and similar expressions are intended to identify forward-looking statements.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements involve risks, uncertainties, and other assumptions that may cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in our filings with the SEC. We undertake no obligation to update any forward-looking statements.

By their nature, forward-looking statements involve risks and uncertainties. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those expressed or implied by these forward-looking statements.

Investor Relations Contact:
Chris Tyson, Executive Vice President
MZ Group – MZ North America
949-491-8235
PHUN@mzgroup.us
www.mzgroup.us

Presentation to Cover the 50 MW, 12-Year Nebius Agreement and Expansion of Contracted Power Capacity to 120 MW

CFO Jolienne Halisky to Participate in October 19 Panel Discussion

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — AIB Data Centers Inc. (NYSE American: AIB) (“AIB” or the “Company”), a developer and operator of digital infrastructure focused on artificial intelligence (“AI”) and high-performance computing (“HPC”) workloads, today announced that Chief Financial Officer Jolienne Halisky and Vice President of Sales Gary Heitz will host an in-person presentation and one-on-one investor meetings at the LD Micro 20th Annual Main Event, taking place October 19–21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Ms. Halisky will also participate in a panel discussion on Monday, October 19.

The presentation will focus on AIB’s recently announced binding agreement with Nebius (Nasdaq: NBIS), under which the Company will provide 50 MW of critical IT capacity at its data center site in the southeastern United States over an initial 12-year term.

Management will discuss the project’s development and financing strategy, including customer prepayments that, together with project-level debt and preferred equity, are expected to fund a substantial portion of initial development costs. This structure is expected to significantly reduce AIB’s need for corporate-level common equity and limit potential shareholder dilution.

LD Micro Main Event XX
Date: October 20–21, 2026
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA
Conference Website: Click here
Format: In-person Presentation, Panel and 1×1 meetings
Presentation: Wednesday, October 21, 2026, 11:30 a.m. PT (2:30 p.m. ET), Track 2
Panel: Monday, October 19, 2026
Webcast Registration: Click here
Attendees: Chief Financial Officer Jolienne Halisky and Vice President of Sales Gary Heitz

To schedule a one-on-one meeting with AIB Data Centers management, please contact your conference representative, email your request to AIB@mzgroup.us, or call Chris Tyson at (949) 491-8235.

About AIB Data Centers

AIB Data Centers Inc. is a developer and operator of digital infrastructure focused on AI hosting and high-performance computing workloads. The Company’s platform combines access to reliable, scalable power resources with modular infrastructure deployment designed to accelerate the development of next-generation compute capacity.

For more information on AIB Data Centers, please visit www.aib.us.

Safe Harbor / Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s participation in upcoming investor events, the development and delivery of contracted capacity, the expected sources and timing of project funding, its contracted power portfolio, and its development pipeline and growth strategy. These statements are based on management’s current expectations and are subject to risks and uncertainties, including the availability of capital, customer demand, the timing and completion of utility construction and interconnection work, and other factors described in the Company’s filings with the Securities and Exchange Commission. Actual results may differ materially.

Investor Relations Contact:
Chris Tyson, Executive Vice President
MZ Group – MZ North America
949-491-8235
AIB@mzgroup.us
www.mzgroup.us

The EM&T Board and executives will publicly showcase the largest high-performance rare earth magnet facility in production outside China as U.S. defense, drone, and automotive demand for non-China supply accelerates, ahead of January 1, 2027 DFARS sourcing restrictions and the planned U.S. expansion

MIAMI, FL, Oct. 05, 2026 (GLOBE NEWSWIRE) — Evolution Metals & Technologies Corp. (“EM&T” or the “Company”) (Nasdaq: EMAT), a U.S.-based critical materials and advanced manufacturing company, today announced that the Company will publicly showcase the largest high-performance rare earth magnet facility in production outside of China, at a ribbon-cutting ceremony on Thursday, December 17, 2026, in Pohang, South Korea. The flagship facility anchors the Company’s phased expansion of annual rare earth magnet production capacity, targeting more than 10,000 metric tons, and positions EM&T as a scaled, non-China source of high-performance rare earth permanent magnets for U.S. defense, unmanned aircraft systems (UAS), and automotive supply chains across the United States and allied markets.

Showcase Highlights:

• Largest high-performance rare earth magnet facility in production outside China, located in Pohang, South Korea
• Phased expansion targeting more than 10,000 metric tons of annual rare earth magnet production capacity
• Positioned ahead of DFARS 252.225-7052, effective January 1, 2027, restricting Chinese-origin rare earth magnets in qualifying U.S. defense systems
• Follows the August 13, 2026 White House proclamation imposing a 100 percent tariff on the most sensitive foreign unmanned aircraft and certain parts
• Strategic offtake and trade discussions with defense and automotive commercial partners on site
• Live magnet making, guided production-line tours, and an executive operational briefing on December 17, 2026
  

The operational showcase and ribbon-cutting ceremony will take place from 1:00 p.m. to 4:00 p.m. (KST) at the Company’s Pohang facility (46, Blue Seoro 2-gil, Donghae-myeon, Nam-gu, Pohang-si, Gyeongsangbuk-do, Republic of Korea). Confirmed attendees include senior government dignitaries, institutional investors, defense and automotive commercial partners, Company leadership, and international media. The program will feature an executive operational briefing, guided technical tours of active production lines and live magnet making, formal addresses by visiting dignitaries, and a ribbon-cutting ceremony. The afternoon will conclude with executive interviews, bilateral discussions to explore strategic offtake and trade opportunities, and an executive networking reception featuring live music and traditional Korean barbecue. A live webcast of the executive operational briefing will be available at investors.evolution-metals.com.

“On December 17, we will publicly inaugurate what we believe is the largest high-performance magnet facility in production outside of China,” said David Wilcox, Executive Chairman of EM&T. “This is a first step in taking production the Company has already proven in Korea to the next level. With DFARS 252.225-7052 taking effect on January 1, 2027 to restrict Chinese-origin rare earth magnets in qualifying U.S. defense systems, and following the August 13, 2026, White House proclamation imposing a 100 percent tariff on the most sensitive foreign unmanned aircraft and certain parts, the demand for secure supply chains is urgent. EM&T is built to serve as that definitive manufacturing solution for the United States and its partnered commercial markets. Pohang is where that solution is already running at commercial scale, and it is the platform from which we will build in the United States.”

“Our Pohang facility represents the operational foundation for EM&T’s next phase of commercial growth,” said Frank Moon, Chief Executive Officer of EM&T. “The plant is intended to support the expansion of annual rare earth magnet production to more than 10,000 metric tons per annum, from the operating base the Company already runs in Korea. That is the scale this next stage of production requires. Defense, unmanned aircraft, and automotive customers are seeking secure, non-China magnet supply, and Pohang is where EM&T is producing it today.”

To attend the event in Pohang, South Korea, please RSVP to RSVP@evolution-metals.com.

About Evolution Metals & Technologies Corp.
Evolution Metals & Technologies Corp. (Nasdaq: EMAT) is a U.S.-based critical materials and advanced manufacturing company for rare earth permanent magnets, battery materials, and related critical minerals and technologies. By leveraging proven commercial-scale operations, advanced processing technologies, and strategic partnerships, EM&T operates what it believes is the only vertically integrated critical materials supply chain spanning end-of-life electronics and batteries, high-grade concentrates, and the manufacture of finished rare earth magnets (including high-performance rare earth magnets) and battery materials. For additional information, please visit investors.evolution-metals.com and follow the Company on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the ribbon-cutting ceremony on Thursday, December 17, 2026, including its timing, format, attendance, program, and live magnet making; the Company’s characterization of the Pohang facility; the planned expansion of annual rare earth magnet production capacity in Pohang toward approximately 10,000 metric tons; the January 1, 2027 effective date and scope of DFARS 252.225-7052 and the Company’s ability to help address related sourcing needs; the August 13, 2026 White House proclamation on unmanned aircraft systems and its parts and components, and the demand for rare earth permanent magnets that may result; the Company’s planned U.S. buildout; and EM&T’s strategy, business plans, and growth opportunities. These forward-looking statements, together with terms such as anticipate, expect, intend, may, will, should, believe, plan, and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such risks include, among others, changes to the event date, time, program, venue, or attendance; delays in facility readiness, equipment installation, or commissioning; the Company’s ability to conduct live magnet making as planned; changes in the DFARS 252.225-7052 effective date, scope, or waiver practices; changes in tariff rates, scope, or timing applicable to unmanned aircraft and their parts; the availability of feedstock, working capital, and customer qualifications; the Company’s ability to execute its planned U.S. expansion; and the other risks described in EM&T’s filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these statements, which speak only as of the date made. EM&T undertakes no obligation to update any forward-looking statement except as required by law. Additional information concerning factors that may affect EM&T’s expectations and projections is contained in its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, filed with the SEC on August 17, 2026, including the disclosures under “Risk Factors” therein, and other documents filed or to be filed with the SEC by EM&T. SEC filings are available at www.sec.gov.

Investor Relations Contacts
Arx Investor Relations
North American Equities Desk
www.arxhq.com
EMAT@arxhq.com

PR, Marketing & Global Partnerships:
Phoenix MGMT & Consulting
PR@PhoenixMGMTConsulting.com
888-228-0122

BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on October 1, 2026 to two new employees as a material inducement to employment under Bicara’s 2026 Inducement Plan.

The employees received, in the aggregate, non-qualified stock options to purchase 207,150 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $18.20 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on October 1, 2026. One-fourth of the options vest on the first anniversary of the employee’s applicable start date, with the remaining options vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.

All of the above-described awards were granted outside of Bicara’s stockholder-approved equity incentive plans and are pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The awards were approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Tim Palmer
Tim.Palmer@bicara.com